SCHEDULE: Biotech Fund Adjusts Nektar Therapeutics Stake

Several Biotechnology Value Funds have updated their beneficial ownership filings for Nektar Therapeutics, reporting a combined stake of 7.1% as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Nektar Therapeutics' common stock.
• Multiple Biotechnology Value Funds (BVF, BVF2, Trading Fund OS) and their associated entities (BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc.) are reporting their holdings.
• As of June 30, 2026, the aggregate beneficial ownership reported by these entities is 7.1% of Nektar Therapeutics' outstanding common stock.
• This represents a total of 2,391,075 shares held by entities including BVF Partners L.P./IL and BVF Inc./IL, with Mark N. Lampert also holding a beneficial interest.
• The filing references Nektar Therapeutics' outstanding shares as of May 1, 2026, which was 33,786,032 shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership percentage without new strategic information or financial performance data.

Positives

• The filing clearly outlines the beneficial ownership stakes of several investment entities in Nektar Therapeutics.
• The reporting is structured and provides specific share counts and percentages for each reporting entity.

Negatives

• The filing does not contain any new financial performance data, strategic updates, or forward-looking guidance from Nektar Therapeutics.
• It is an informational filing regarding ownership changes, not an indicator of company performance or future prospects.

Risks

• The filing does not explicitly mention any risks associated with Nektar Therapeutics or the reporting entities' investments.

Future Outlook

This filing is an amendment to a Schedule 13G and does not contain forward-looking statements or guidance from Nektar Therapeutics.

Management Comments

• Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common in the biotechnology sector, often indicating significant institutional investment. The aggregated stake reported here by various Biotechnology Value Funds suggests sustained interest in Nektar Therapeutics, though the filing itself provides no insight into the underlying scientific or commercial progress of the company.

Related Party Transactions

• BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 2,197,386 Shares beneficially owned in the aggregate by BVF and BVF2.
• Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 2,391,075 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account.
• BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,391,075 Shares beneficially owned by Partners.
• Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 2,391,075 Shares beneficially owned by BVF Inc.

Stakeholder Impact

• Shareholders may note the significant aggregate stake held by the Biotechnology Value Funds, which could influence market perception or future corporate actions, although no specific impact is detailed.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Nektar Therapeutics, Biotechnology Value Fund, Schedule 13G, Beneficial Ownership, Investment Fund, Common Stock, Securities Exchange Act